Cardiol Therapeutics Inc. ( (CRDL) ) has released its Q4 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™. In its latest earnings report, Cardiol Therapeutics Inc. reported a net loss of $36.7 million for 2024, an increase from the $28.1 million loss in 2023. The company’s cash and cash equivalents decreased to $30.6 million from $34.9 million in the previous year. Key financial highlights include a significant rise in general and administrative expenses to $26.3 million from $15.6 million, while research and development expenses remained stable at approximately $14 million. The company also raised $21.4 million through a public offering of common shares. Looking ahead, Cardiol Therapeutics remains committed to advancing its clinical programs and exploring strategic opportunities to enhance shareholder value.